Eutilex CEO Choi Soo-young (third from the right), NA Vaccine Research Institute CEO Kim Dong-ho (third from the left) and other officials are taking a commemorative photo after the MOU. (Provided by Eutilex)

[Edaily Reporter Kim Ji-wan] Eutilex announced on the 7th that it signed a memorandum of understanding (MOU) with the NA Vaccine Institute for joint research on cancer immunotherapy

Through this MOU, Eutilex will work with the NA Vaccine Institute on research and development to improve the tumor cell recognition and attack power of antibody and T cell therapies. In addition, when conducting clinical development of CAR-T cell therapy, we plan to explore combination research with NexaVant, NAVI's T cell activator.

Dong-ho Kim, CEO of NA Vaccine Institute, said, “We are happy to be conducting joint research with Eutilex, which is aggressively conducting cancer immunotherapy research and clinical trials based on its solid technology,” and added, “I hope it will create synergy in the development of Eutilex’s cancer immunotherapy.” said..

Eutilex CEO Choi Soo-young said, “We are collaborating with the NA Vaccine Institute, which possesses technology that is substantially helpful in improving the treatment effect and accelerating the development of Eutilex’s cancer immunotherapy.” “I believe that NA Vaccine Institute’s NexaVac and NexaVant will serve as an opportunity for the development of new anti-cancer treatments beyond improving the treatment effectiveness of Eutilex’s various cancer immunotherapy,” he said.